Pipeline

A first-in-class antisense drug designed to reduce LDL-cholesterol. Mipomersen is currently being evaluated in a broad Phase 3 program in patients who cannot adequately control their cholesterol levels. Learn More >

An antisense drug to inhibit CRP, a protein that is dramatically increased during inflammatory disorders and excessive amounts have also been linked to coronary artery disease. We plan to initiate a broad Phase 2 program in 2010. Learn More >

An antisense drug being developed by BMS designed to inhibit PCSK9, an important protein involved in the metabolism of cholesterol. Our partner, BMS, intends on initiating Phase 1 studies this year. Learn More >

An antisense drug designed to treat clotting disorders. It targets Factor XI, a clotting factor produced in the liver. High levels of Factor XI are linked to heart attack, stroke and blood clots. Learn More >

An antisense drug that inhibits ApoC-III, a protein that is responsible for triglyceride transport in blood. High levels of ApoC-III are linked to inflammation, atherosclerosis and metabolic syndrome. Learn More >

An antisense drug to inhibit PTP-1B, an insulin sensitizer for the treatment of type 2 diabetes. In addition to lowering glucose, ISIS 113715 has anti-obesity and lipid-lowering potential. We reported positive top-line Phase 2 data on ISIS 113715 in 2009 and will report the full data at an upcoming scientific meeting. Learn More >

An antisense drug being developed by OMJPI designed to inhibit GCGR, a hormone that opposes the action of insulin and stimulates the liver to produce glucose. Learn More >

An antisense drug being developed by OMJPI designed to inhibit GCCR, a hormone that has a variety of effects throughout the body, including promoting liver glucose production and fat storage. Learn More >

An antisense drug to inhibit SGLT2, a major transporter for blood sugar reabsorption in the kidney. ISIS-SGLT2_Rx is currently being evaluated in a Phase 1 study designed to access the safety and activity of the drug in healthy volunteers. Learn More >

An antisense drug being developed by Teva and OncoGenex and is designed to inhibit clusterin, a secreted protein that acts as a cell-survival protein and is overexpressed in response to cancer treatments, like chemotherapy, hormone ablation and radiation therapy. Teva and OncoGenex will collaborate on a global Phase 3 clinical program for OGX-011 in patients with prostate and non-small cell lung cancer. Learn More >

An antisense drug being developed by Eli Lilly & Company designed to inhibit survivin, a protein that plays a role in inhibiting the growth of cancer cells and is one of the most common overexpressed proteins in cancer. Learn More >

An antisense drug to inhibit eIF-4E, a protein that is overexpressed in a variety of cancers and is involved in key growth and survival factors that contribute to tumor progression and the spread of cancer. A Phase 1 study in patients with cancer showed that ISIS-EIF4E_Rx was well tolerated and we plan to initiate a broad Phase 2 program on the drug. Learn More >

An antisense drug being developed by OncoGenex designed to inhibit Hsp27, a cell-survival protein that is overexpressed in response to many cancer treatments. OGX-427 is currently being evaluated in a Phase 1 study in patients with various cancers who have failed potentially curative treatments or for which curative treatments do not exist. Learn More >

An antisense drug to inhibit SOD1, a protein associated with an inherited, aggressive form of ALS. We expect ISIS-SOD1_Rx to enter Phase 1 clinical studies this year. Learn More >

An antisense drug designed to treat spinal muscular atrophy, which is caused by a genetic deletion of a gene responsible for producing a protein critical for normal cellular function. ISIS-SMN_Rx increases the production of this protein by modulating the splicing of a closely related gene, thereby compensating for the underlying genetic defect. Learn More >

An antisense drug to inhibit ICAM-1, an intracellular adhesion molecule that is overexpressed in a wide variety of inflammatory disorders. Learn More >

An antisense drug being developed by Teva and designed to inhibit VLA-4, a protein involved in a number of inflammatory diseases, including MS. Teva is completing additional preclinical studies to support long-term dosing in patients with MS prior to continuing to a Phase 3 study. Learn More >

An inhaled antisense drug being developed by Altair designed to inhibit two important cytokines in asthma that regulate inflammation, mucus overproduction and airway hyper-responsiveness. AIR645 is currently being evaluated in clinical development. Learn More >

An antisense drug designed to treat CMV retinitis in AIDS patients. Vitravene demonstrates our ability to meet FDA and European regulatory requirements for safety and efficacy, and for the commercial manufacture of antisense drugs. Learn More >

A neoglycoside drug being developed by Achaogen for the treatment of multi-drug resistant gram-negative bacterial infections. Learn More >

An antisense drug being developed by iCo designed to inhibit c-raf kinase, a kinase associated with the reduction and leakage of new blood vessels in the eye. Learn More >

An antisense drug being developed by ATL designed to inhibit GHr. GHr is a receptor that reduces the level of a circulating hormone, which has been shown to contribute to various diseases, including acromegaly, a disease characterized by abnormal growth of organs, face, hands and feet. Learn More >

An antisense drug being developed by Excaliard for the treatment of fibrotic diseases, including scarring. EXC 001 is currently in multiple Phase 2 studies. Learn More >